Neuritic plaques in the brains are one of the pathological hallmarks of Alzheimer ' s disease (AD). Amyloid ␤ -protein (A ␤ ), the central component of neuritic plaques, is derived from ␤ -amyloid precursor protein (APP) after ␤ -and ␥ -secretase cleavage. The molecular mechanism underlying the pathogenesis of AD is not yet well defi ned, and there has been no effective treatment for AD. Valproic acid (VPA) is one of the most widely used anticonvulsant and mood-stabilizing agents for treating epilepsy and bipolar disorder. We found that VPA decreased A ␤ production by inhibiting GSK-3 ␤ -mediated ␥ -secretase cleavage of APP both in vitro and in vivo. VPA treatment signifi cantly reduced neuritic plaque formation and improved memory defi cits in transgenic AD model mice. We also found that early application of VPA was important for alleviating memory defi cits of AD model mice. Our study suggests that VPA may be benefi cial in the prevention and treatment of AD.
Alzheimer ' s disease (AD) is the most common neurodegenerative disorder leading to dementia. Neuritic plaques, neurofi brillary tangles, and neuronal loss represent the main histological hallmarks observed in AD brains. Amyloid ␤ -protein (A ␤ ), the central component of senile plaques, is produced from sequential endoproteolytic cleavages of the type 1 transmembrane glycoprotein ␤ -amyloid precursor protein (APP) by ␤ -and ␥ -secretase ( 1 ) . ␤ -Site APP cleaving enzyme 1 (BACE1) is the ␤ -secretase in vivo ( 2 -6 ) . ␥ -Secretase is an atypical multimeric membrane-protein aspartic protease composed of at least four subunits: presenilin (PS1 or PS2), nicastrin (Nct), APH-1 (APH-1aL, APH-1aS, or APH-1b), and PEN-2 ( 7 -11 ). More recently, two additional proteins, CD147 and TMP21, were found to be closely associated with the ␥ -secretase complex ( 12, 13 ) .The components of the ␥ -secretase complex are tightly regulated with each other, and PS1 is generally believed to be its catalytic core ( 14, 15 ) . Another important substrate of ␥ -secretase is Notch, whose intracellular domain (NICD) is released upon ␥ -secretase cleavage and translocates to the nucleus, where it can activate transcription of downstream target genes ( 8, 10 ) . In addition to its role in Notch signaling and APP processing, ␥ -secretase is also involved in regulating intramembraneous proteolysis of many other type I integral membrane proteins, such as Jagged, Delta, Ecadherin, ErbB-4, Nectin-1 ␣ , CD44, and LRP ( 16 -22 ) . Missense mutations in the PS1 and PS2 genes are major causes of early-onset familial AD ( 23 -25 ) . Although the underlying mechanism of AD neurodegeneration is currently unclear, A ␤ accumulation appears to play a critical role in AD pathogenesis. P < 0.001, respectively; Fig. S2 ). APP23 mice were also treated with VPA at 9 mo of age. Signifi cantly more neuritic plaques were formed in the mice at 9 mo compared with 7 mo of age; however, VPA treatment starting at the age of 9 mo could also signifi cantly reduce neuritic plaque formation ( Fig. 1 A,  c and d ) . The number of plaques in VPA-treated and control mice were 11.09 ± 0.92 and 25.60 ± 3.50, respectively (P < 0.005; Fig. 1 E ) . The area of plaques was also signifi cantly reduced in VPA-treated mice compared with control by 43.10 ± 11.13% for the 7-mo-old group (P < 0.01) and by 59.66 ± 5.44% for the 9-mo-old group (P < 0.05). In addition to reducing neuritic plaque formation, VPA treatment also signifi cantly increased microtubule-associated protein (MAP)-2 immunoreactivity ( Fig. 1 C ) , which indicated a protective effect on dendritic damages and promoting neurite outgrowth in the transgenic mice. Similar results were obtained with silver staining (unpublished data).
To further confi rm VPA ' s eff ect on AD pathogenesis, APP23 transgenic mice were crossbred with PS45 transgenic mice to generate APP23/PS45 double-transgenic mice. PS45 mice have an overexpression of the human familial AD-associated G384A mutant presenilin-1. The double-transgenic mice developed detectable neuritic plaques in the neocortex and hippocampus as early as 1 mo of age. Double-transgenic mice were treated with 30 mg/kg VPA at 6 wk of age for 4 wk. VPA treatment markedly inhibited neuritic plaque formation ( Fig. 1 A, f and d ) and signifi cantly reduced plaque numbers from 14.84 ± 1.67 to 2.862 ± 0.65 (P < 0.0001; Fig. 1 F ) . Thiofl avin S staining also confi rmed VPA-induced reduction of A ␤ -containing neuritic plaque formation in the brains of APP23 single-transgenic ( Fig. 1 B, b and a ) and APP23/PS45 double-transgenic ( Fig. 1 B, d and c ) mice. Over the 4-wk injection period, VPA treatment did not aff ect food and water consumption of the mice, and no signifi cant weight changes were observed between the treatment and control groups (unpublished data). These data clearly demonstrate that VPA inhibits A ␤ neuritic plaque formation in vivo.
VPA treatment signifi cantly improves memory defi cits in AD model mice To investigate whether VPA treatment aff ects learning and memory in AD pathogenesis, behavioral tests were performed after APP23 mice received 1 mo of VPA treatment starting at the age of 7 mo. The Morris water maze was used to determine the eff ect of VPA on spatial memory. In the visible platform tests, VPA-treated and control APP23 mice had similar escape latency (53.190 ± 1.56 and 49.75 ± 2.47 s; P > 0.05; Fig. 2 A ) and path length (7.03 ± 1.33 and 6.78 ± 1.60 s; P > 0.05; Fig. 2 B ) , which indicated that VPA treatment did not aff ect mouse motility or vision. In the hidden platform-swimming test, APP23 mice treated with VPA showed signifi cant improvements compared with the vehicle-treated controls. The escape latency on the third and fourth day of the hidden platform test was shorter (15.95 ± 1.61 and 12.80 ± 1.83 s) than nontreated APP23 mice (29.04 ± 2.99 and 24.89 ± 3.33 s; P < 0.001; Fig. 3 C ) . The VPA-treated mice were able to Valproic acid (VPA) is one of four fi rst-line antiepileptic drugs being increasingly used in the treatment of bipolar disorder. Like other anticonvulsants, VPA inhibits sodium, potassium, and calcium channel functions. Although its direct in vivo target has yet to be defi nitively identifi ed ( 26 ) , VPA may enhance ␥ -aminobutyric acid transmission ( 27 ) . VPA has been found to activate extracellular signal-regulated kinase, a protein kinase known to regulate AP-1 function, and mediate neurotrophic responses ( 28 ) . VPA treatment could lead to a change in glycogen synthase kinase (GSK-3) and histone deacetylase (HDAC) activity ( 29 ) . Furthermore, VPA, like lithium, regulates the Wnt signaling pathway by increasing ␤ -catenin expression ( 30 ) . Increased ␤ -catenin expression is also seen after treatment with the chemically unrelated HDAC inhibitor trichostatin A. This mechanism may explain some eff ects of VPA on gene expression and neurodevelopment ( 31 ) . It has been shown that increased histone acetylation by HDAC inhibitors facilitates synaptogenesis and improves learning and memory, suggesting that inhibition of HDAC may be a suitable therapeutic avenue for neurodegenerative diseases ( 32 ) .
In this study, we examined the eff ects of VPA on AD neuropathology and behavioral defi cits and identifi ed its underlying mechanism. We found that VPA inhibited GSK-3 ␤ -mediated ␥ -secretase cleavage of APP both in vitro and in vivo. Furthermore, such inhibition decreased A ␤ production and neuritic plaque formation, as well as alleviated the memory defi cits in AD transgenic model mice. Our data suggest that VPA is eff ective for antiamyloid therapy in the prevention and treatment of AD.
RESULTS

VPA inhibits A ␤ deposition and neuritic plaque formation in AD transgenic mice
To assess the eff ect of VPA treatment on AD neuropathology, APP23 transgenic mice, which are an AD mouse model, were subjected to VPA treatment. APP23 mice carry the human Swedish mutant APP751 transgene driven by the neuronalspecifi c Thy1.2 promoter (Fig. S1 , available at http://www .jem.org/cgi/content/full/jem.20081588/DC1). APP23 mice develop amyloid plaques in the neocortex and hippocampus as early as 6 mo ( 33 ). APP23 mice were treated with 30 mg/kg VPA at 7 mo of age, whereas age-matched control APP23 mice received vehicle solution. To investigate whether VPA treatment could result in neuropathological changes in vivo, VPA-treated and control mice were killed after treatment and behavioral tests. 4G8 immunostaining and thiofl avin S staining were used to detect A ␤ -containing neuritic plaques in the brain ( Fig. 1, A and B ). Neuritic plaque formation was signifi cantly decreased in APP23 mice treated with VPA ( Fig. 1 A, b ), relative to controls ( Fig. 1 A, a ) . Quantifi cation showed that overall VPA treatment reduced plaque number by ‫ف‬ 4-fold (3.5 ± 0.79 vs. 14.95 ± 2.09 per slice; P < 0.0001; Fig.  1 D ) . The eff ects were similar among mice killed either immediately, 1 mo, or 2 mo after treatment and behavioral testing (0.75 ± 0.48 vs. 5.50 ± 1.32, P < 0.001; 2.33 ± 0.50 vs. 10.33 ± 1.26, P < 0.001; and 5.30 ± 1.33 vs. 21.5 ± 02.76, 0.01; Fig. 2 D ) . In the probe trial on the last day of testing, the platform was removed. VPA treatment signifi cantly improved the AD mouse ' s spatial memory. The number of times the swim signifi cantly shorter distances to reach the platform (3.88 ± 0.91 and 2.68 ± 1.02 m) compared with control mice (6.03 ± 0.94 and 5.37 ± 1.38 m) on the third and fourth day (P < Figure 1 . VPA treatment signifi cantly reduces neuritic plaque formation in AD transgenic mice. (A) APP23 mice at the age of 7 or 9 mo and APP23/PS45 double-transgenic mice at the age of 6 wk were treated with 30 mg/kg VPA for 4 wk, whereas age-matched control APP23 mice received the vehicle solution. The mice were killed after behavioral tests and the brains were dissected, fi xed, and sectioned. Neuritic plaques were detected using an A ␤ -specifi c monoclonal antibody 4G8 and the DAB method. The plaques were visualized by microscopy with 40X magnifi cation. The number of neuritic plaques was signifi cantly reduced in VPA-treated mice compared with controls. b, d, and f show the representative brain section of the 7-mo APP23 age group, 9-mo APP23 age group, and APP23/PS45 mice treated with VPA, and a, c, and e show their controls, respectively. Black arrows point to plaques. (D) Quantifi cation of neuritic plaques in APP23 mice with treatment starting at the age of 7 mo, the number represents mean ± SEM. n = 30 mice each. *, P < 0.0001 by Student ' s t test. (E) Quantifi cation of neuritic plaques in APP23 mice with treatment starting at the age of 9 mo, the number represents mean ± SEM. n = 12 mice each. *, P < 0.005 by Student ' s t test. (F) Quantifi cation of neuritic plaques in APP23/PS45 mice with treatment starting at the age of 6 wk, the number represents mean ± SEM. n = 25 mice for control and 29 mice for VPA. *, P < 0.0001 by Student ' s t test.
latency and path length in the hidden platform trial of the Morris water maze test between the treatment and control groups (P > 0.05). Although VPA treatment only slightly improved performance in the hidden platform tests in the APP23/PS45 double-transgenic mice, VPA treatment significantly improved performance in the probe trial (7.13 ± 0.70 and 3.43 ± 1.13; P < 0.05).
mice traveled into the third quadrant, where the hidden platform was previously placed, was significantly greater with VPA treatment compared with control (9.56 ± 2.62 and 4.18 ± 1.06; P < 0.005; Fig. 2 E ) . These data indicate that VPA treatment signifi cantly improves the memory defi cits seen in APP23 mice. Because VPA treatment stopped a day before and there was no treatment during the behavioral testing, the eff ect of VPA on the behavioral performance in the mice was not just acute, but also long lasting.
Behavioral tests were also performed on the older APP23 mice administered with VPA at the age of 9 mo to assess their cognitive function. Despite a signifi cant reduction in plaque formation, there were no signifi cant diff erences in the escape The VPA-treated and control APP23 mice had similar swimming distances before escaping onto the visible platform in the visible platform test. P > 0.05 by Student ' s t test. (C) In hidden platform tests, mice were trained with 6 trials per day for 4 d. VPA-treated APP23 mice showed a shorter latency to escape onto the hidden platform on the third and fourth day. P < 0.001 by ANOVA. (D) The VPA-treated APP23 mice had a shorter swimming length before escaping onto the hidden platform on the third and fourth day. P < 0.01 by ANOVA. (E) In the probe trial on the sixth day, the VPA-treated APP23 mice traveled into the third quadrant, where the hidden platform was previously placed, signifi cantly more times than controls. *, P < 0.005 by Student ' s t test. Half brains from VPA-treated and control APP23 mice of the 7-mo age group were lysed in RIPA-Doc lysis buffer and separated with 16% Tris-Tricine SDS-PAGE. APP full-length and CTFs (C99 and C83) were detected by C20 polyclonal antibody. PS1 was detected by anti-PS1 Nterminal antibody 231. Total A ␤ was isolated from the brain tissues with 4G8 monoclonal antibody and detected using 6E10 anti-A ␤ monoclonal antibody. ␤ -Actin was detected by anti -␤ -actin antibody AC-15 as the internal control. (B) Quantifi cation showed that CTFs were signifi cantly increased, whereas A ␤ levels were markedly reduced in VPA-treated mice. n = 30 each for control and VPA group. *, P < 0.05 by Student ' s t test. ELISA assay was performed to measure A ␤ 40 (C) and A ␤ 42 (D) levels in the conditioned media of primary neuronal cultures derived from the brain tissues of newborn APP23/PS45 mice. The cells were cultured for a week before VPA treatment for 24 h. n = 3. *, P < 0.005 by Student ' s t test. (E) Swedish mutant APP stable cell line 20E2 was cultured and treated with different doses of VPA for 24 h, and cell lysates were subjected to Western blot analysis. C99 and C83 were detected with C20 antibody. ␤ -Actin was detected by anti -␤ -actin antibody AC-15 as the internal control. (F) Quantifi cation of CTF (C99 and C83) generation in 20E2 cells. VPA treatment signifi cantly increased APP CTF production. n = 4. *, P < 0.001 by ANOVA. (G) APP C99 stable cell line H99C1 was treated with different doses of VPA for 24 h, and the CTFs (C99, C89, and C83) were detected by 9E10 antibody. ␤ -Actin was detected by anti -␤ -actin antibody AC-15 as the internal control. (H) Quantifi cation of CTFs (C99, C89, and C83) levels in H99C1 cells. VPA treatment signifi cantly increased APP CTF production. n = 4. *, P < 0.001 by ANOVA. mice, likely by regulating APP processing through inhibition of ␥ -secretase activity. To further investigate the underlying mechanism of VPA ' s eff ect, we fi rst examined its eff ect on APP, BACE1, and PS1 gene expression. Our data show that VPA treatment did not change the mRNA levels of these genes ( Fig. 4, A -C ) . Previous studies suggested that GSK-3 ␤ regulated A ␤ formation ( 35 -37 ) . GSK-3 ␤ activity is regulated by its phosphorylation at the serine 9 (S 9 ) and tyrosine 216 sites (Y 216 ). The S 9 phosphorylation (pGSK-3 ␤ S9 ) inhibits GSK-3 ␤ activity, whereas the Y 216 phosphorylation (pGSK-3 ␤ Y216 )
VPA alters APP processing and inhibits A ␤ production in vivo and in vitro
Our data clearly demonstrated that VPA treatment inhibited neuritic plaque formation and improved the memory defi cits in the AD model mice. To investigate the underlying mechanism, we examined the eff ect of VPA on APP processing. The level of APP C-terminal fragments (CTFs) and A ␤ in the mouse brain tissues was assayed by Western blot analysis ( Fig. 3 A ) . VPA treatment signifi cantly increased the levels of APP CTFs. The levels of ␤ -secretase -generated C99 and ␣ -secretase -generated C83 fragments were increased by 227.7 ± 36.8% in the brains of VPA-treated mice relative to controls (P < 0.05; Fig.  3 B ) . Furthermore, the production of A ␤ was signifi cantly inhibited by VPA, and the total A ␤ level was decreased to 18.71 ± 6.24% in the brains of VPA-treated mice relative to controls (P < 0.05; Fig. 3 B ) . The A ␤ ELISA assay was also performed to measure A ␤ 40 and A ␤ 42 levels in the transgenic brain tissues. The levels of A ␤ 40 and A ␤ 42 were reduced to 67.64 ± 2.89 and 34.53 ± 1.53% in VPA-treated mice relative to controls, respectively (P < 0.05). To further confi rm VPA ' s eff ect on A ␤ production, we measured A ␤ 40 and A ␤ 42 levels in the conditioned media of cultured primary cortical and hippocampal neurons derived from neonatal APP23/PS45 double-transgenic mice. VPA markedly reduced A ␤ generation, decreasing A ␤ 40 and A ␤ 42 levels to 48.86 ± 1.52 and 58.90 ± 3.43%, respectively, relative to controls (P < 0.005; Fig. 3, C and D ) . VPA treatment had no signifi cant eff ect on APP and PS1 protein levels ( Fig. 3, A and B ) . The increased C99 and C83 levels, together with the decreased A ␤ production in the brains of the VPA-treated transgenic mice, indicate that VPA inhibits ␥ -secretase cleavage of APP proteins.
To examine the eff ect of VPA on APP processing in vitro, 20E2 and H99C1 cells were treated with VPA. Consistent with in vivo data from transgenic mouse models, VPA significantly increased APP C99 and C83 generation in 20E2 cells, which are a HEK293 stable cell line overexpressing the Swedish mutant APP ( Fig. 3 E ) ( 34 ) , and the levels of total CTFs were increased by 140.58 ± 5.5, 138.3 ± 5.58, 176.7 ± 2.73, and 179.64 ± 4.10% with 0.5, 1.5, 5, and 10 mM of VPA treatment, respectively (P < 0.001; Fig. 3 F ) . To further confirm the inhibitory effect of VPA on ␥ -secretase cleavage of APP, H99C1 cell line was established to stably overexpress APP C99, a major ␤ -secretase cleavage product of APP (Fig. S3 , available at http://www.jem .org/cgi/content/full/jem.20081588/DC1). VPA treatment signifi cantly increased the levels of APP CTFs, including C99, C89, and C83 ( Fig. 3 G ) . The levels of total CTFs were increased by 200.59 ± 4.10, 244.09 ± 3.87, 354.36 ± 17.30, and 400.24 ± 17.63% with 0.5, 1.5, 5, and 10 mM of VPA treatment, respectively (P < 0.001; Fig. 3 H ) . These data clearly indicated that VPA inhibited ␥ -secretase processing of APP C99 protein.
VPA inhibits GSK-3 activity
Our data demonstrated that VPA signifi cantly decreased A ␤ production and neuritic plaque formation in AD transgenic Figure 4 . VPA inhibits GSK-3 ␤ activity. Total RNA was isolated from N2a cells by TRI-Reagent (Sigma-Aldrich). A set of gene-specifi c primers were used to amplify APP (A), BACE1 (B), and PS1 (C) genes. ␤ -Actin was used as an internal control. There was no difference in endogenous APP, PS1, or BACE1 mRNA levels between VPA-treated cells and controls. (D) Brain tissues from APP23/PS45 double-transgenic mice were subjected to Western blot analysis to determine the levels of total GSK-3 ␤ and phospho -GSK-3 ␤ S9 . VPA increases phospho -GSK-3 ␤ S9 (P Ser9 ) levels, but not total GSK-3 ␤ levels in the transgenic mice. (E) N2a cells were treated with 5 mM of VPA for 0, 6, 12, and 24 h and lysed in RIPA-Doc buffer containing a series of serine and tyrosine phosphatase inhibitors. The cell lysates were subjected to Western blot analysis using a rabbit anti -phospho-GSK-3 ␤ Ser-9 antibody. Kodak Image Analysis software was used to quantify protein level. n = 3. *, P < 0.001 by ANOVA. (F) Total GSK-3 ␤ level was also measured. (G) Promoter assay. pTOPFLASH plasmid was cotransfected with pcDNA3-␤ -catenin and pcDNA3-Tcf expression plasmids into N2a cells. pCMV-Rluc was also cotransfected to normalize transfection effi ciency. Luciferase assay was performed 48 h after transfection. Promoter activity was indicated by the luciferase activity. VPA increased ␤ -catenin-Tcf mediated transcription activation. n = 4. *, P < 0.005 by Student ' s t test.
developing axons but also increased axonal branching and formation of curved axons ( 43 ) . We show that VPA not only inhibits neuritic plaque formation but also promotes neurite outgrowth in the transgenic mice.
There have been VPA clinical trials conducted on AD patients. Profenno et al. reported that doses of < 1,000 mg/d of divalproex sodium could be tolerated by patients in a Safety and Tolerability trial of 20 outpatients with probable AD ( 44 ) . In a clinical trial conducted on 14 moderate to severe institutionalized AD patients with a mean age of 85.6 yr that assessed VPA ' s eff ect on agitation and aggression, VPA treatment was found to be ineff ective for the management of agitation and aggression ( 45 ) . These reports had little data that addressed VPA ' s eff ect on AD pathogenesis, neuropathology, and cognitive impairments. Consistent with a previous work which showed that both lithium and VPA inhibited A ␤ production in a Swedish mutant APP751 stable cell line and PDAPP (APPV717F) transgenic mice ( 37 ), we systematically demonstrated that in two diff erent transgenic AD mouse models, VPA has signifi cant beneficial eff ects on AD pathogenesis. VPA reduced ␥ -secretase cleavage of APP and A ␤ production in vitro and in vivo, resulting in the prevention of AD-associated pathological outcomes. Furthermore, our data showed that early administration of VPA not only reduced neuritic plaque formation, but also rescued some memory defi cits in AD transgenic mice. Meanwhile, we found that the inhibitory eff ect of VPA on neuritic plaque formation was present up to 2 mo after discontinuing administration of VPA, indicating VPA ' s long lasting antiamyloid treatment potential for AD patients. However, when mice were treated with VPA at a later stage, when there was profound neuritic plaque formation, VPA could still reduce further neuritic plaque formation, albeit a lesser eff ect on improving memory defi cits in the older mice. Our preclinical animal study indicated that VPA can have eff ects on neuropathology changes at early and late stages, but cognitive impairments can only be improved at an early stage intervention. These data suggest that VPA treatment should be applied at early stages of AD pathogenesis for eff ective improvement of pathological and cognitive impairments. This information may also provide insights for VPA clinical trial designs. Our animal study suggests that the VPA trial might not show benefi cial results on late or severe AD patients, whereas it might show signifi cant improvements in early or mild AD patients.
MATERIALS AND METHODS
Transgenic mice and VPA treatment. Animal experiment protocols were approved by The University of British Columbia Animal Care and Use committee. APP23 transgenic mice carry human APP751 cDNA with the Swedish double mutation at positions 670/671 (KM → NL) under control of the murine Thy-1.2 expression cassette ( 33 ) . PS45 transgenic mice carry human presenilin-1 cDNA with the M146V mutation. The genotype of the mice was confi rmed by PCR using DNA from tail tissues. Mice were injected with 30 mg/kg VPA i.p. at the same time each day. Control mice were injected with PBS as a vehicle. We tabulated daily food and water consumption for each mouse.
up-regulates GSK-3 ␤ activity. To examine whether GSK-3 ␤ mediated VPA ' s eff ect on APP processing in AD transgenic model mice, brain tissues of the double-transgenic mice were subjected to Western blot analysis for total GSK-3 ␤ and phospho-GSK-3 ␤ levels. We found no diff erences in total GSK-3 ␤ protein levels between the VPA treatment and control mice groups; however, VPA treatment also signifi cantly increased GSK-3 ␤ S9 levels in vivo ( Fig. 4 D ) . Consistent with the transgenic mouse data, VPA treatment in vitro also significantly facilitated the phosphorylation of GSK-3 ␤ at the S9 site. The level of phospho-GSK-3 ␤ S9 in VPA-treated N2a cells was increased to 147.87 ± 12.38 and 181.18 ± 16.55% after 12-and 24-h treatment (P < 0.001; Fig. 4 E ) , whereas VPA had little eff ect on total GSK-3 ␤ level in N2a cells (P > 0.05; Fig. 4 F ) . Further phosphorylation screening by the Kinetworks 1.3 KPSS Phospho-site Profi ling revealed that pGSK-3 ␤ Y216 levels were markedly reduced by 37%. Collectively, these data suggest that VPA negatively regulates GSK-3 ␤ activity. To examine the eff ect of VPA on GSK-3 ␤ -mediated biological function, we performed a ␤ -catenin-Tcf reporter gene assay. Phosphorylated ␤ -catenin by GSK-3 is rapidly degraded by the ubiquitin proteasome pathway, therefore inhibition of GSK-3 stabilizes ␤ -catenin and activates downstream gene transcription. TOPFLASH, containing three copies of the optimal Tcf motif CCTTTGATC upstream of a minimal c -Fos promoter driving luciferase expression ( 38 ) , were cotransfected with ␤ -catenin and Tcf expression plasmids into N2a cells. VPA treatment signifi cantly potentiated ␤ -cateninmediated transcriptional activation, resulting in higher promoter activity (138.80 ± 1.37%; P < 0.005; Fig. 4 G ) . The up-regulatory eff ect of VPA was abolished when the cells were transfected with mutant ␤ -catenin cDNA. Collectively, our data indicate that regulation of APP processing and neuritic plaque formation by VPA may be mediated by its eff ect on the GSK-3 ␤ signaling pathway.
DISCUSSION
There has been no eff ective method for the treatment or prevention of AD. Inhibition of HDAC activity with pharmacological agents demonstrated limited levels of synaptogenesis and improved learning and memory ( 32 ) . Preclinical studies suggested that inhibition of A ␤ production by altering APP processing at the ␤ -or ␥ -secretase site by lithium or nonsteroidal antiinfl ammatory drugs could potentially be avenues for AD drug development ( 30, 39, 40 ) . Here, we show that VPA, an antiepileptic drug, can serve as a highly eff ective antiamyloid treatment in AD transgenic model mice. VPA can inhibit GSK-3 ␤ , resulting in increased ␤ -catenin protein levels ( 41, 42 ) . GSK-3 ␤ is a key component of the Wnt signaling pathway, controlling ␤ -catenin levels and transcriptional responses required for development and cell growth. Consistent with previous reports, we found that VPA inhibited GSK-3 ␤ activity by altering its phosphorylation state. VPA was also found to inhibit HDAC activity ( 29 ) , which could improve learning and memory ( 32 ) . Previous reports showed that VPA treatment not only induced synapsin I clustering in RT-PCR. RNA was isolated from cells using TRI-Reagent (Sigma-Aldrich). PowerScript reverse transcription (Invitrogen) was used to synthesize the fi rst-strand cDNA from an equal amount of the RNA sample following the manufacturer ' s instruction. The newly synthesized cDNA templates were further amplifi ed by Platinum Tag DNA polymerase (Invitrogen) in a 25-μ l reaction. The following primers were used to specifi cally amplify APP, PS1, and BACE1 genes: BACE1, forward 5 Ј -ACCGACGAAGAGTCG-GAGGAG-3 Ј and reverse 5 Ј -CACAATGCTCTTGTCATAG-3 Ј ; APP, forward 5 Ј -CGGAATTCCCTTGGTGTTCTTTGCAGAAG-3 Ј and reverse 5 Ј -CGGAATTCCGTTCTGCATCTCTCAAAG-3 Ј ; PS1, forward 5 Ј -GGATCCGCCACCATGGTGTGGTTGGTGAATATGGC-3 Ј and reverse 5 Ј -CGGGATCCCTAGATATAAAATTGATGG-3 Ј .
␤ -Actin was used as an internal control. The samples were analyzed on a 1.2% agarose gel.
Kinetwork KPSS 1.3 PhosphoSite analysis. N2A cells were treated with 5 mM of VPA for 12 h, followed by homogenizing in lysis buff er containing 0.5% Triton X-100, 2 mM EGTA, 5 mM EDTA, 20 mM MOPS, 200 mM sodium orthovanadate, 25 mM ␤ -glycerophosphate, 20 mM sodium pyrophosphate, 30 mM sodium fluoride, 1 mM PMSF, and 1 complete mini protease inhibitor cocktail tablet (Roche Diagnostics). The samples were diluted in 4 × SDS-sample buff er to give a fi nal protein concentration of 1 μ g/ μ l. The samples were then boiled and sent to Kinexus Bioinformatics Corp. for the Kinetworks KPSS 1. Online supplemental material. Fig. S1 shows the genotyping of the AD transgenic mice. Fig. S2 shows the results of VPA ' s eff ect on plaque formation in diff erent age groups of APP23 mice. Fig. S3 shows the generation of human APP C99 stable cell line H99C1. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20081588/DC1.
